Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors.
The aim of this study was to evaluate the treatment outcomes of stereotactic body radiation therapy for treating primary or metastatic thoracic tumors using a stereotactic body frame. Between January 1998 and February 2004, 101 lesions from 91 patients with thoracic tumors were prospectively reviewed. A dose of 10-12 Gy per fraction was given three to four times over consecutive days to a total dose of 30-48 Gy (median 40 Gy). The overall response rate was 82%, with 20 (22%) complete responses and 55 (60%) partial responses. The one- and two-year local progression free survival rates were 90% and 81%, respectively. The patients who received 48 Gy showed a better local tumor control than those who received less than 48 Gy (Fisher exact test; p = 0.004). No pulmonary complications greater than a RTOG toxicity criteria grade 2 were observed. The experience of stereotactic body frame based radiation therapy appears to be a safe and promising treatment modality for the local management of primary or metastatic lung tumors. The optimal total dose, fractionation schedule and treatment volume need to be determined after a further follow-up of these results.
Yoon
Sang Min
SM
Department of Radiation Oncology, Asan Medical Center, College of Medicine, University of Ulsan, 388-1 Pungnap-Dong, Songpa-Gu, Seoul, 138-736, Korea.
Choi
Eun Kyung
EK
Lee
Sang-Wook
SW
Yi
Byong Yong
BY
Ahn
Seung Do
SD
Shin
Seong Soo
SS
Park
Heon Joo
HJ
Kim
Su Ssan
SS
Park
Jin-Hong
JH
Song
Si Yeol
SY
Park
Charn Il
CI
Kim
Jong Hoon
JH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D016634:Radiosurgery / Q000295:instrumentation*; D015996:Survival Rate; D013899:Thoracic Neoplasms / Q000601:surgery*; D016896:Treatment Outcome